(Q64650568)
Statements
A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period (English)
0 references
February 2011
0 references
September 2012
0 references
201
0 references
60 year
0 references
85 year
0 references